文献速递浆细胞疾病造血干细胞移植与细胞治疗

新型CAR γδ T细胞抗多发性骨髓瘤的研制及单细胞RNA测序分析

The development of novel chimeric antigen receptor gamma-delta T cells against multiple myeloma and single-cell RNA sequencing analysis.
PubMed 文献 · Br J Haematol · 2026-07-12

本研究开发了靶向BCMA的新型CAR γδ T细胞,并与CAR αβ T细胞进行功能对比。结果显示CAR γδ T细胞抗原刺激后活化相似,但增殖能力和细胞毒性持久性较低,体内需更高剂量才能达到与CAR αβ T细胞相当的肿瘤控制。单细胞转录组揭示抗原刺激后循环CAR γδ T细胞比例低限制其持久性。

要点

  • 新型BCMA CAR γδ T细胞体外可有效杀伤骨髓瘤细胞。
  • CAR γδ T细胞增殖能力和细胞毒性持久性低于CAR αβ T细胞。
  • 含CD3ε或CD3ζ胞内域的CAR构建体细胞毒性和体内疗效更优。

核心结论

  • 新型CAR γδ T细胞体外有效清除MM细胞,但体内持久性有限,需进一步工程化解决增殖瓶颈。

研究设计与样本

  • 开发靶向BCMA的新型CAR γδ T细胞,并与CAR αβ T细胞进行功能测定比较。
  • 进行体内实验评估肿瘤控制效果,并采用单细胞转录组分析。

主要发现

  • CAR γδ T细胞抗原刺激后活化与CAR αβ T细胞相似,但增殖能力较低、细胞毒性持久性较差。
  • 体内需更高剂量CAR γδ T细胞才能达到与CAR αβ T细胞相当的肿瘤控制。
  • 含CD3ε或CD3ζ胞内域的CAR构建体表现出更优的细胞毒性和体内疗效。
  • 单细胞转录组显示抗原刺激后循环CAR γδ T细胞比例低,限制了其持久性。

临床怎么用

  • γδ T细胞可作为现货型平台,但需进一步工程化改造以克服增殖瓶颈。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) gamma-delta (γδ) T cells offer a major histocompatibility complex-independent, off-the-shelf alternative to conventional CAR alpha-beta (αβ) Tcells, but their efficacy in multiple myeloma (MM) remains underexplored. In this work, we developed a series of novel CAR γδ T cells redirected to B-cell maturation antigen (BCMA) and performed functional assays compared to CAR αβ T cells. As a result, novel CAR γδ T cells demonstrated similar activation upon antigen stimulation compared with CAR αβ T cells but showed lower proliferative capacity and less durable cytotoxicity. In vivo, higher doses of CAR γδ T cells were required to achieve tumour control comparable to CAR αβ T cells. Among CAR constructs, those with cluster of differentiation 3 (CD3ε or CD3ζ) intracellular domain exhibited superior cytotoxicity and in vivo efficacy. Single-cell transcriptomic profiling revealed the low ratio of cycling CAR γδ T cells after antigen stimulation limited the persistence of CAR γδ T cells. In conclusion, our developed novel CAR γδ T cells effectively eliminated MM cells in vitro, but exhibited limited in vivo persistence compared to traditional CAR αβT cells. These findings establish a baseline for utilizing γδ T cells as an off-the-shelf platform and highlight that addressing the proliferation bottleneck through further engineering is essential for future clinical translation.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Hong Y, Zhang C, Wang J, et al. The development of novel chimeric antigen receptor gamma-delta T cells against multiple myeloma and single-cell RNA sequencing analysis. Br J Haematol. 2026. PMID: 42438316. doi:10.1111/bjh.70660

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。